{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-042511","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.318582+00:00","generated_at":"2026-05-30T10:09:11.213203+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mira Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical neuropathy study","bullets":["Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain.","Company plans additional preclinical studies targeting diabetic neuropathy and PTSD.","Exploring government funding opportunities to support the development program."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-042511","json":"https://secwatch.observer/filing/0001493152-24-042511.json","markdown":"https://secwatch.observer/filing/0001493152-24-042511.md","text":"https://secwatch.observer/filing/0001493152-24-042511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/0001493152-24-042511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:09:11.213203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}